

Replacement of dietary saturated fat with unsaturated fats increases numbers of circulating endothelial progenitor cells and decreases number of microparticles: findings from the randomized, controlled DIVAS study

Article

Accepted Version

Weech, M. ORCID: <https://orcid.org/0000-0003-1738-877X>, Altowaijri, H., Mayneris-Perxachs, J., Vafeiadou, K., Madden, J., Todd, S. ORCID: <https://orcid.org/0000-0002-9981-923X>, Jackson, K. G. ORCID: <https://orcid.org/0000-0002-0070-3203>, Lovegrove, J. A. ORCID: <https://orcid.org/0000-0001-7633-9455> and Yaqoob, P. ORCID: <https://orcid.org/0000-0002-6716-7599> (2018) Replacement of dietary saturated fat with unsaturated fats increases numbers of circulating endothelial progenitor cells and decreases number of microparticles: findings from the randomized, controlled DIVAS study. *American Journal of Clinical Nutrition*, 107 (6). pp. 876-882. ISSN 0002-9165 doi: <https://doi.org/10.1093/ajcn/nqy018> Available at <https://centaur.reading.ac.uk/75013/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1093/ajcn/nqy018>

Publisher: American Society for Nutrition

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

Replacement of dietary saturated fat with unsaturated fats increases numbers of circulating endothelial progenitor cells and decreases numbers of microparticles: findings from the randomised, controlled DIVAS study^{1,2,3,4}

Michelle Weech, Hana Altowaijri, Jordi Mayneris-Perxachs, Katerina Vafeiadou, Jacqueline Madden, Susan Todd, Kim G. Jackson, Julie A. Lovegrove, Parveen Yaqoob

¹Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences and Institute for Cardiovascular and Metabolic Research (MW, HA, J M-P, KV, JM, KGJ, JAL, PY) and Department of Mathematics and Statistics (ST), University of Reading, Whiteknights, Reading, UK

Weech, Altowaijri, Mayneris-Perxachs, Vafeiadou, Madden, Todd, Jackson, Lovegrove, Yaqoob

²**Disclaimers:** JAL is a member of the UK Scientific Advisory Committee on Nutrition (SACN) and the SACN sub-committee for ‘Saturated fat and Healthy’, she also chairs the ILSI committee on saturated fats and cardiovascular disease.

³**Corresponding author:** Professor Parveen Yaqoob, Department of Food & Nutritional Sciences, University of Reading, Whiteknights PO Box 226, Reading, RG6 6AP, UK. Telephone: +44(0)118 3788720; Email: P.Yaqoob@reading.ac.uk

⁴**Sources of Support:** Funded by the United Kingdom Food Standards Agency and Department of Health Policy Research Programme (024/0036). Unilever R&D produced and supplied in kind

the study spreads and oils according to our specification, but was not involved in the design, implementation, analysis or interpretation of the data.

Running head: Dietary fat, progenitor cells and microparticles

Abbreviations: %TE, percentage of total energy; AIx, augmentation index; CRP, C reactive protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; DIVAS, Dietary Intervention and VAScular function; EPC, endothelial progenitor cells; EMP, endothelial microparticles; FMD, flow-mediated dilatation; MP, microparticles; PMP, platelet microparticles.

Clinical Trials Registry number: NCT01478958 (clinicaltrials.gov)

1 **Abstract**

2 **Background**

3 Endothelial progenitor cells (EPC) and microparticles (MP) are emerging novel markers of
4 cardiovascular disease (CVD) risk, which could potentially be modified by dietary fat. We have
5 previously shown that replacing dietary saturated fat (SFA) with monounsaturated (MUFA) or n-
6 polyunsaturated fat (PUFA) improved lipid biomarkers, blood pressure and markers of
7 endothelial activation, but their effects on circulating EPCs and MPs are unclear.

8 **Objective**

9 The Dietary Intervention and VAScular function (DIVAS) study investigated the replacement of
10 9.5-9.6% total energy (%TE) SFA with MUFA or n-6 PUFA for 16 weeks on EPC and MP
11 numbers in UK adults with moderate CVD risk.

12 **Design**

13 In this randomized, controlled, single-blind, parallel group dietary intervention, men and women
14 aged 21-60 y ($n=190$) with moderate CVD risk ($\geq 50\%$ above the population mean) consumed one
15 of three 16-week isoenergetic diets. Target compositions for total fat, SFA, MUFA and n-6
16 PUFA (%TE) were: SFA-rich diet (36:17:11:4, $n=64$), MUFA-rich diet (36:9:19:4, $n=62$) and n-6
17 PUFA-rich diet (36:9:13:10, $n=66$). Circulating EPC, endothelial MP (EMP) and platelet MP
18 (PMP) numbers were analysed by flow cytometry. Dietary intake, vascular function and other
19 cardio-metabolic risk factors were determined at baseline.

20 **Results**

21 Relative to the SFA-rich diet, MUFA and n-6 PUFA-rich diets decreased EMP (-47.3%, -44.9%)
22 and PMP numbers (-36.8%, -39.1%) (overall diet effects $P<0.01$). The MUFA-rich diet increased
23 EPC numbers (+28.4%; $P=0.023$). Additional analyses using stepwise regression models

24 identified the augmentation index (measuring arterial stiffness determined by pulse wave
25 analysis) as an independent predictor of baseline EPC and MP numbers.

26 **Conclusions**

27 Replacing 9.5-9.6% TE dietary SFA with MUFA increased EPC numbers and replacement with
28 either MUFA or n-6 PUFA decreased MP numbers, suggesting beneficial effects on endothelial
29 repair and maintenance. Further studies are warranted to determine the mechanisms underlying
30 the favourable effects on EPC and MP numbers following SFA replacement.

31

32 **Keywords:** Endothelial progenitor cells, Microparticles, Saturated fat, Monounsaturated fat,
33 Polyunsaturated fat

34 **Introduction**

35 Endothelial dysfunction occurs when the balance between endothelial injury and repair is
36 disrupted (1). Microparticles (MP) are small (0.1-1 μ m) cell-derived vesicles released from the
37 surface of many cell types, including endothelial cells and platelets, during apoptosis or
38 activation, which may occur during endothelial injury. There is growing evidence for their use as
39 diagnostic biomarkers for cardiovascular diseases (CVD) and their potential as pharmacological
40 targets (2). Although present in healthy subjects, MP numbers are elevated in individuals with
41 CVD and associated risk factors (2, 3), and addition of endothelial MP (EMP) numbers to the
42 Framingham risk score model improves its prediction power of future CVD events (4). The
43 impact of dietary and lifestyle factors on MP numbers is unclear. High fat meals acutely increase
44 numbers of MP (5, 6), particularly when containing SFA and thermally-oxidised PUFA (7),
45 supporting the well-accepted relationship between postprandial lipemia and endothelial activation
46 (8). Very few studies have examined the chronic effects of dietary fat composition on MP
47 numbers; we recently demonstrated decreased numbers of EMP, but not platelet microparticles
48 (PMP), following fish oil supplementation (9).

49 While MP are associated with endothelial injury, circulating bone marrow-derived
50 endothelial progenitor cells (EPC) home to sites of endothelial injury where they induce
51 neovascularization (10), potentially playing an important role in preserving the structural and
52 functional integrity of the endothelium. Reduced EPC numbers and function are associated with
53 CVD risk factors, including hypertension and hypercholesterolemia, and there is interest in the
54 potential role of EPC as prognostic and/or diagnostic markers of CVD. However, clear data
55 regarding the influence of dietary fat quality on the balance between endothelial injury and repair
56 is limited.

57 Reduction of SFA intake to $\leq 10\%$ of total energy (%TE) is a key public health strategy to
58 reduce CVD risk (11). Replacing SFA with unsaturated fat, rather than carbohydrate, may afford
59 greater CVD risk reduction (12, 13), yet it is not clear whether MUFA or n-6 PUFA have
60 comparable effects on risk reduction or on emerging cellular markers of CVD risk (14). We
61 recently demonstrated in the Dietary Intervention and VAScular function (DIVAS) study that
62 substituting 9.5-9.6 %TE dietary SFA with either MUFA or n-6 PUFA did not significantly affect
63 flow-mediated dilatation (FMD; primary outcome), but there were beneficial effects on lipid
64 biomarkers, blood pressure and circulating E-selectin (15). Since the modification of dietary fat
65 intake affects cellular markers of vascular function in the absence of alterations in FMD and
66 previous studies suggest an impact of dietary fat composition on EPC numbers, this article
67 presents additional outcome measures from the DIVAS study exploring the effect of substituting
68 SFA with MUFA or n-6 PUFA on circulating EPC and MP numbers in subjects with moderate
69 CVD risk. Multiple regression analyses also determined which dietary and CVD risk factors
70 influence numbers of EPC and MP at baseline.

71 **Methods**

72 **Study participants and design**

73 The protocol for the DIVAS study has been described in full by Vafeiadou et al. (15). In
74 summary, the study was a single-blind, randomized controlled parallel group study
75 (NCT01478958) conducted according to the guidelines laid down in the Declaration of Helsinki.
76 A favourable ethical opinion for conduct was given by the West Berkshire Local Research Ethics
77 Committee (09/H0505/56) and the University of Reading Research Ethics committee (project
78 number 09/40). Subjects provided written informed consent before participating. Non-smoking
79 males and females aged 21-60 y with moderate CVD risk were recruited from Reading and the
80 surrounding area in three cohorts between November 2009 and June 2012. A scoring tool
81 described by Weech et al. identified individuals with a moderate risk of developing CVD ($\geq 50\%$
82 above the population mean) (16). Further inclusion criteria included normal blood biochemistry
83 for liver and kidney function, not taking dietary supplements, not taking medication for
84 hypertension, hypercholesterolemia, hyperlipidemia or inflammatory disorders, had not suffered
85 from a myocardial infarction or stroke during the past 12 months or been diagnosed with
86 diabetes, not pregnant or lactating, not consuming excessive amounts of alcohol (≤ 21 units for
87 males and ≤ 14 units for females) and not participating in excessive amounts of aerobic exercise
88 ($\leq 3 \times 20$ min per week).

89

90 **Dietary intervention**

91 The food-exchange model for the dietary intervention has been described by Weech et al. (16). In
92 brief, participants ($n=202$) were randomized (using minimization to match for age, gender, BMI
93 and CVD risk score) to one of three 16 week intervention diets that aimed to replace 8% TE SFA
94 with MUFA or n-6 PUFA. The target fatty acid compositions (as %TE) were as follows: SFA-

95 rich diet (17% SFA, 11% MUFA and 4% n-6 PUFA); MUFA-rich diet (9% SFA, 19% MUFA
96 and 4% n-6 PUFA); or n-6 PUFA-rich diet (9% SFA, 13% MUFA and 10% n-6 PUFA). All three
97 isoenergetic diets provided 36% TE total fat, and n-3 PUFA, protein and carbohydrate were
98 unchanged. The main sources of fats in the intervention diets were butter (SFA), refined olive oil
99 and olive oil/rapeseed oil blended spread (MUFA) and safflower oil and spread (n-6 PUFA).
100 Subjects were blinded to the diet allocation. Dietary intakes were determined from four day
101 weighed diet diaries completed at baseline (week 0) and during the intervention (weeks 8 and 16),
102 which were analyzed using Dietplan 6.6 (Foresfield, Horsham, UK). Following the intervention,
103 target intakes were met or exceeded, and a greater replacement of SFA for MUFA (9.5% TE) and
104 n-6 PUFA (9.6% TE) was achieved (16). For simplicity, the SFA-rich, MUFA-rich and n-6
105 PUFA-rich diets will be referred to as the SFA, MUFA and n-6 PUFA diets going forward.

106

107 **Clinical and Biochemical analyses**

108 As described in full by Vafeiadou et al. (15), volunteers attended the Hugh Sinclair Unit of
109 Human Nutrition (University of Reading, UK) at baseline (visit 1) and week 16 (visit 2)
110 following an overnight fast. At each visit, non-invasive measurements of vascular function were
111 performed: FMD (primary outcome), laser Doppler imaging with iontophoresis, pulse wave
112 velocity, pulse wave analysis (determining the augmentation index (AIx)), and digital volume
113 pulse (determining the stiffness and reflection indexes). 24 h ambulatory blood pressure and
114 anthropometric measurements were also recorded. Fasting serum lipids, glucose and C-reactive
115 protein (CRP) were analyzed using an ILAB600 clinical chemistry analyzer (Werfen UK Ltd,
116 Warrington, UK). Insulin resistance was determined using HOMA-IR (17), and 10 y CVD risk
117 was estimated using the validated QRISK[®]2-2013 CVD risk calculator (<http://qrisk.org>) (18).
118 Plasma insulin and circulating markers of endothelial activation and inflammation (intercellular

119 adhesion molecule-1, vascular cell adhesion molecule-1, IL-6, TNF α , sE-selectin, sP-selectin,
120 and von Willebrand Factor) were analyzed by commercial ELISA kits, plasma nitric oxide by
121 chemiluminescence (15), and plasma phospholipid fatty acid composition by gas chromatography
122 (16). Results for these outcome measures in response to the dietary intervention have been
123 discussed previously (15, 16) and will not be presented again here.

124 **Enumeration of EPC, EMP and PMP**

125 EPC, EMP and PMP were analyzed by flow cytometry as previously described (9). CD34⁺KDR⁺
126 cells were defined as EPC and expressed as number of cells/mL of blood. EMP were defined as
127 CD31⁺CD42b⁻ particles and PMP as CD31⁺CD42b⁺ particles, both reported as counts/ μ L of
128 blood.

129 **Statistical analysis**

130 The sample size was powered on the basis of a 2% (SD 2.3%) intergroup difference in %FMD,
131 which was the primary outcome as reported in (15), with a 5% significance level and power of
132 90%. At this level of power, 171 participants were required ($n=57$ per group), which increased to
133 228 to include a 25% dropout rate ($n=76$ per group). This article reports further secondary
134 outcomes of the DIVAS study (EPC and MP). For continuous variables, suitable checks of
135 normality were implemented as appropriate. Differences between the diet groups at baseline were
136 determined using one-way ANOVA and Chi-squared tests (gender). The General Linear Model
137 was used to analyze the change from baseline (V2-V1) for EPC, EMP, and PMP when comparing
138 the three dietary groups. The model included the baseline values of each corresponding variable
139 of interest, age, gender, BMI and diet group as prognostic factors. Where the overall diet effect
140 was significant, differences between diet groups were determined by post-hoc analyses using the

141 Tukey adjustment for multiple treatment comparisons to control for type 1 errors, and one sample
142 t-tests determined whether the change from baseline was significantly different to zero for each
143 diet. Statistical significance was assumed if $P \leq 0.05$ and statistical analyses were performed using
144 SPSS version 21.0 (SPSS Inc.). In the tables and text, data are expressed as mean \pm SE or %
145 changes. LSMeans \pm SE are presented in the figures.

146
147 Stepwise regression analysis was performed as an additional analysis to determine which
148 independent CVD risk factors influenced numbers of EPC, EMP or PMP using pre-intervention
149 baseline (V1) data. Independent factors included the DIVAS outcome measures (vascular
150 function, 24 h ambulatory blood pressure, biochemical markers of CVD risk and anthropometric
151 measures), dietary factors (macronutrient intakes (as %TE) and plasma phospholipid fatty acid
152 composition), CVD risk scores (DIVAS scoring tool and QRISK), age, gender, menstrual status,
153 family history of early onset type 2 diabetes mellitus or myocardial infarction, and ethnicity (15,
154 16). To avoid multicollinearity, only the most clinically-relevant independent factor was included
155 where a pair of independent variables were highly correlated (two-tailed Spearman's correlation
156 coefficients) and a variance inflation factor of <5 was set. Only related independent variables,
157 where $P < 0.15$ following an initial linear regression between the dependent (EPC, EMP or PMP)
158 and independent variable, were used in the corresponding stepwise regression model. Stepwise
159 selection of variables used entry and removal parameters of $F < 0.05$ and $F > 0.10$, respectively, and
160 missing values were excluded listwise. Unstandardized β coefficients \pm SE are presented, where
161 $P < 0.05$ (determined by t-tests) were considered significant.

162 **Results**

163 Of the 202 subjects randomized to the intervention (the flow of participation is presented in
164 **Supplemental Figure 1**), seven subjects withdrew from the study before completion and EPC
165 and MP data was not available for five subjects ($n=190$). There were no differences in the
166 baseline characteristics of the subjects between the diet groups (**Table 1**). The combined mean (\pm
167 SE) age was 44 ± 1 y and BMI was 26.6 ± 0.3 kg/m².

168

169 **Effect of replacement of SFA with MUFA or n-6 PUFA on EPC numbers**

170 There were no significant differences in baseline EPC numbers between the three intervention
171 groups (**Supplemental Table 1**). When expressed as changes from baseline (V2-V1), there was a
172 significant overall effect of diet for EPC ($P=0.023$). Post-hoc analysis showed that when
173 compared with the SFA group, EPC numbers significantly increased by 28.4% in the MUFA
174 group after 16 weeks ($P=0.017$) (**Supplemental Table 1** and **Figure 1A**). No differences were
175 observed between the n-6 PUFA group and the MUFA or SFA groups. Furthermore, within-
176 group analysis showed that the MUFA diet significantly increased EPC numbers by 27.3%
177 compared with baseline ($P \leq 0.001$), but the SFA (-1.1%; $P=0.846$) and n-6 PUFA (+9.1%;
178 $P=0.130$) diets had little impact on EPC numbers.

179 **Effect of replacement of SFA with MUFA or n-6 PUFA on MP numbers**

180 At baseline, EMP and PMP numbers were similar in the three intervention groups (**Supplemental**
181 **Table 1**). There were significant overall diet effects for changes in EMP and PMP numbers (both
182 $P \leq 0.001$). When SFA was replaced by MUFA, numbers of EMP decreased by 47.3% ($P \leq 0.001$)
183 and PMP by 36.8% ($P=0.002$) after 16 weeks (**Figures 1B** and **1C**). Likewise, an exchange of
184 SFA for n-6 PUFA reduced numbers of EMP (-44.9%; $P \leq 0.001$) and PMP (-39.1%; $P \leq 0.001$).

185 There were no differences between the MUFA and n-6 PUFA groups for EMP or PMP. Within-
186 group differences from baseline further revealed significant reductions in EMP (-30.1%; P
187 ≤ 0.001) and PMP (-22.4%; $P \leq 0.001$) following the n-6 PUFA diet. The MUFA diet also resulted
188 in reductions in EMP (-32.5%; $P \leq 0.001$) and PMP (-20.1%; $P = 0.002$) relative to baseline.
189 Finally, the SFA diet increased numbers of EMP (+14.7%; $P = 0.010$) and tended to increase PMP
190 (+16.7%; $P = 0.073$) after 16 weeks.

191

192 **Influence of CVD risk factors on numbers of circulating EPCs and MPs at baseline**

193 To determine which CVD risk factors influence numbers of EPCs and MPs, stepwise regression
194 analysis was performed using the pre-intervention data collected at baseline (V1). This defined
195 the total variance explained by the independent predictors identified in the model (r^2 adjusted)
196 and the impact that 1 unit change of the independent variable had on EPC or MP numbers
197 (unstandardized β). Three independent factors were identified that predicted higher EPC
198 numbers: reduced arterial stiffness as measured by AIx ($\beta = -18.0$ (SE(β)= 4.6), $P < 0.001$), a
199 higher night-time diastolic blood pressure (DBP) ($\beta = 18.7$ (SE(β)= 7.7), $P = 0.016$) and a lower
200 dietary total sugar intake ($\beta = -19.5$ (SE(β)= 9.4), $P = 0.039$) (**Supplemental Table 2**). However,
201 this model only explained 11.0% of the variance for EPC. Four predictors were identified that
202 predicted higher EMP, explaining 14.5% of the variance. These were increased arterial stiffness
203 (AIx: $\beta = 0.72$ (SE(β)= 0.21), $P = 0.001$), higher plasma P-selectin ($\beta = 0.55$ (SE(β)= 0.20), $P =$
204 0.007) and TNF α concentrations ($\beta = 9.03$ (SE(β)= 3.99), $P = 0.025$), and lower CRP ($\beta = -1.95$
205 (SE(β)= 0.73), $P = 0.008$). For the final model (explaining only 5.2% of the variance), high PMP
206 numbers were also predicted by higher AIx ($\beta = 2.58$ (SE(β)= 1.12), $P = 0.023$) as well as lower
207 microvascular reactivity (measured by laser Doppler imaging with iontophoresis of 1%
208 acetylcholine) ($\beta = -0.04$ (SE(β)= 0.02), $P = 0.029$).

209 **Discussion**

210 This study demonstrates, for the first time, that substituting 9.5-9.6%TE of dietary SFA with
211 MUFA in free-living adults for 16 weeks significantly increases numbers of EPC and substitution
212 with either MUFA or n-6 PUFA decreases numbers of both EMP and PMP, suggesting
213 favourable effects on the repair and maintenance of the endothelium when SFA is substituted for
214 unsaturated fatty acids. Replacement of dietary SFA by MUFA or PUFA is widely believed to
215 reduce the risk of CVD, more so than if SFA are replaced by carbohydrate (13). A recent review
216 concluded that ‘the benefits of polyunsaturated fat appear strongest’, but this comment relates to
217 both n-6 and n-3 PUFA (19), and the available data on MUFA interventions with hard endpoints
218 is limited. One such study (PREDIMED) reported that greater intakes of MUFA-rich olive oil,
219 particularly the extra-virgin varieties, significantly reduced CVD risk and mortality in individuals
220 at high cardiovascular risk (20). Although the individual effects of MUFA and n-6 PUFA on
221 CVD risk remain unclear, there is often active discouragement of high intakes of n-6 PUFA
222 (>10%TE) and a preference for MUFA as a strategy to prevent CVD (21).

223 To our knowledge, no other chronic study has determined the impact of replacing SFA
224 with n-6 PUFA. In the current study, there was a reduction in MP when SFA were replaced with
225 n-6 PUFA. In contrast, a n-6 PUFA-rich meal (sunflower oil) increased postprandial circulating
226 CD144-EMP in healthy subjects relative to a SFA-rich meal (cream), although clearly this was an
227 acute setting and the sample size was small ($n=22$) (22). While there are two published studies
228 supporting a reduction in numbers of MPs and increase in numbers of EPCs following a MUFA-
229 rich diet (23, 24), the studies were small and technical issues regarding the EPC and MP analysis
230 cast some doubt on the data. The first study, which replaced a SFA-rich diet (38%TE total fat,
231 22%TE SFA (butter) and 12%TE MUFA) with a MUFA-rich Mediterranean diet (38%TE total
232 fat, <10%TE SFA and 24%TE MUFA (virgin olive oil)) in 20 elderly subjects for 4 weeks,

233 reported higher circulating EPC numbers and lower numbers of total MP (23). In the second
234 study, consumption of a 12-week hypocaloric Mediterranean diet rich in MUFA (30%TE total
235 fat, 5%TE SFA, 20%TE MUFA (virgin olive oil), and 5%TE PUFA) increased EPC numbers
236 relative to baseline in 45 patients with metabolic syndrome (24). However, neither study
237 employed standardized beads to allow absolute counting of samples (23, 24). In addition, Marin
238 et al. (23) failed to describe their gating strategies and presented their EPC data as a percentage,
239 but did not specify what this referred to, making it difficult to assess the validity of the data. The
240 DIVAS study used refined olive oil, being the first to show that increased MUFA intake in the
241 absence of phenolic compounds had beneficial effects on EPC and MP numbers. Since the
242 increase observed in EPC numbers was only significant when SFA was replaced by MUFA,
243 further investigation to understand the different effects of MUFA and n-6 PUFA is warranted.

244 Findings from the baseline regression analyses suggest that AIx, a measure of arterial
245 stiffness, may influence EPC and MP numbers, since an increase in AIx was associated with
246 lower EPC and higher MP numbers. Structural alterations to the arterial walls, such as changes to
247 the elastin to collagen ratio that occur naturally with aging, reduce their elasticity. Increased
248 stiffness puts stress on the arterial walls and increases the risk of plaque rupture, which both
249 enhance the likelihood of CVD events (25). At present, very limited data suggests a link may
250 exist between arterial stiffness and numbers of EPC or MP (26, 27). For example, greater arterial
251 stiffness (as assessed by aortic pulse wave velocity) was reported in subjects with the lowest EPC
252 and highest MP counts, even after controlling for the Framingham risk score (26). Since
253 vasoactive drugs significantly improved AIx in healthy men (28), one could hypothesize that
254 vasodilator drugs may indirectly improve EPC and MP numbers as a means of repairing and
255 maintaining the endothelium, in part via their beneficial effect on AIx, thus lowering CVD risk.
256 This potential relationship warrants further investigation. Higher circulating numbers of EMP

257 were also predicted by greater concentrations of P-selectin and TNF α (markers of endothelial
258 activation and inflammation, respectively). Tan et al. reported a ‘modest’ correlation between
259 PMP and P-selectin ($r= 0.345$, $P <0.001$), both of which were the only predictors of peripheral
260 artery disease severity in multivariate analysis (29). Furthermore, greater concentrations of P-
261 selectin-positive PMP were reported in older adults with CVD compared with young healthy
262 subjects (30), which may facilitate the recruitment of leukocytes and platelets to the endothelium
263 during endothelial dysfunction.

264 The primary outcome of the DIVAS study, FMD, measured macrovascular reactivity, but
265 this was not identified as a predictor of EPC or MP numbers. In contrast, a reduction in
266 microvascular reactivity, as measured by laser Doppler imaging in response to acetylcholine, did
267 appear to have a detrimental impact on PMP numbers, suggesting a potential mechanism relating
268 the regulation of the microcirculation to the release of PMP. However, blood pressure, which is
269 closely related to microvascular reactivity (31), did not appear to impact numbers of PMP.

270 Excessive body weight has previously been associated with decreased numbers of EPCs
271 and increased numbers of MPs (32), and weight reduction is reported to restore EPC numbers
272 (33). However, in the current analysis, which is significantly larger than previous studies, there
273 was no influence of BMI or waist-to-hip ratio at baseline on numbers of EPCs or MPs.
274 Furthermore, the beneficial effects of SFA substitution with unsaturated fats on EPC and MP
275 numbers were not related to changes in weight as there were no differences in BMI or central
276 adiposity between the diet groups after 16 weeks (16). In addition, EPC and MP numbers were
277 not dependent on gender; to our knowledge, this is the first time the influence of gender on
278 numbers of MPs in a large cohort has been investigated. Numbers of EPCs and MPs were also
279 not dependent on age, ethnicity, baseline fasting blood lipids, glucose or insulin. Chronic
280 exposure to CVD risk factors is thought to reduce the mobilization of EPC, thus reducing their

281 numbers in the circulation (34). The subjects recruited into this study were defined as having
282 moderately elevated risk of CVD ($\geq 50\%$ above the population average). Therefore, it is likely
283 that the lack of association with CVD risk factors at baseline was due to the small proportion of
284 subjects identified as being 'at risk' as a result of any one parameter, which could be considered a
285 limitation of the analyses. Further investigation in single 'at risk' populations, e.g. hypertensives
286 or hypercholesteroleemics, is required. The main purpose of the current investigation, however,
287 was to determine the effects of the dietary intervention on numbers of EPC and MP and a key
288 strength was that compared with other studies (23, 24), it was conducted using a much larger
289 sample size ($n=190$ vs $n=20-45$) and as such is the first chronic dietary intervention investigating
290 the effects of exchange of SFA with n-6 PUFA on the newly emerging CVD risk markers, EPC
291 and MP. Finally, multiple treatment comparisons were corrected for using the Tukey adjustment,
292 consistent with the approach taken for the primary outcome analysis of the DIVAS data. It could
293 be suggested that multiple endpoint analysis requires more powerful techniques to control for
294 type 1 errors, such as the false discovery rate, although the need to maintain consistency in our
295 statistical approach with previously published data was considered important in this case (35).

296 In conclusion, a 16-week replacement of 9.5% TE dietary SFA with MUFA increased
297 numbers of EPC and decreased numbers of MP in a population at moderate risk of CVD.
298 Replacement of 9.6% TE dietary SFA with n-6 PUFA did not significantly affect numbers of
299 EPC, but decreased numbers of both EMP and PMP. Further studies investigating SFA
300 replacement are warranted to determine the mechanisms underlying the favourable effects on
301 EPC and MP numbers, and basis for the differential effects of MUFA and n-6 PUFA.

302

303 **Acknowledgements**

304 We would like to thank Rada Mihaylova and Jan Luff, who assisted with recruitment and blood
305 sampling, and Dr Sheila Wu, who conducted some of the EPC and MP analyses.

306

307 The authors' responsibilities were as follows—PY, JAL, KGJ, and ST: designed the study; JM:
308 set up the methods and conducted some of the analysis; MW, KV, HA: conducted the research;
309 MW, HA, JM-P and KV: analyzed the data; ST: provided statistical advice; MW: wrote the
310 manuscript under the guidance of PY, which was modified by all co-authors; PY had primary
311 responsibility for final content. All authors read and approved the final manuscript. None of the
312 authors had a conflict of interest.

References

1. Van Craenenbroeck EM, Conraads VM. Endothelial progenitor cells in vascular health: Focus on lifestyle. *Microvasc Res* 2010;79(3):184-92.
2. Barteneva NS, Fasler-Kan E, Bernimoulin M, Stern JN, Ponomarev ED, Duckett L, Vorobjev IA. Circulating microparticles: square the circle. *BMC Cell Biol* 2013;14:23.
3. Baron M, Boulanger CM, Staels B, Tailleux A. Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation? *J Cell Mol Med* 2012;16(7):1365-76.
4. Nozaki T, Sugiyama S, Koga H, Sugamura K, Ohba K, Matsuzawa Y, Sumida H, Matsui K, Jinnouchi H, Ogawa H. Significance of a Multiple Biomarkers Strategy Including Endothelial Dysfunction to Improve Risk Stratification for Cardiovascular Events in Patients at High Risk for Coronary Heart Disease. *J Am Coll Cardiol* 2009;54(7):601-8.
5. Tushuizen ME, Nieuwland R, Rustemeijer C, Hensgens BE, Sturk A, Heine RJ, Diamant M. Elevated endothelial microparticles following consecutive meals are associated with vascular endothelial dysfunction in type 2 diabetes. *Diabetes Care* 2007;30(3):728-30.
6. Tushuizen ME, Nieuwland R, Scheffer PG, Sturk A, Heine RJ, Diamant M. Two consecutive high-fat meals affect endothelial-dependent vasodilation, oxidative stress and cellular microparticles in healthy men. *J Thromb Haemost* 2006;4(5):1003-10.

7. Sutherland WHF, de Jong SA, Hessian PA, Williams MJA. Ingestion of native and thermally oxidized polyunsaturated fats acutely increases circulating numbers of endothelial microparticles. *Metabolism* 2010;59(3):446-53.
8. Jackson KG, Poppitt SD, Minihane AM. Postprandial lipemia and cardiovascular disease risk: Interrelationships between dietary, physiological and genetic determinants. *Atherosclerosis* 2012;220(1):22-33.
9. Wu SY, Mayneris-Perxachs J, Lovegrove JA, Todd S, Yaqoob P. Fish-oil supplementation alters numbers of circulating endothelial progenitor cells and microparticles independently of eNOS genotype. *Am J Clin Nutr* 2014;100(5):1232-43.
10. Asahara T, Murohara T, Sullivan A, Silver M, vanderZee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997;275(5302):964-7.
11. Hooper L, Summerbell CD, Thompson R, Sills D, Roberts FG, Moore HJ, Smith GD. Reduced or modified dietary fat for preventing cardiovascular disease. *Cochrane Database Syst Rev* 2012;5:CD002137.
12. Jakobsen MU, O'Reilly EJ, Heitmann BL, Pereira MA, Balter K, Fraser GE, Goldbourt U, Hallmans G, Knekt P, Liu SM, et al. Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. *Am J Clin Nutr* 2009;89(5):1425-32.
13. Micha R, Mozaffarian D. Saturated Fat and Cardiometabolic Risk Factors, Coronary Heart Disease, Stroke, and Diabetes: a Fresh Look at the Evidence. *Lipids* 2010;45(10):893-905.

14. Vafeiadou K, Weech M, Sharma V, Yaqoob P, Todd S, Williams CM, Jackson KG, Lovegrove JA. A review of the evidence for the effects of total dietary fat, saturated, monounsaturated and n-6 polyunsaturated fatty acids on vascular function, endothelial progenitor cells and microparticles. *Br J Nutr* 2012;107(3):303-24.
15. Vafeiadou K, Weech M, Altowaijri H, Todd S, Yaqoob P, Jackson KG, Lovegrove JA. Replacement of saturated with unsaturated fats had no impact on vascular function but beneficial effects on lipid biomarkers, E-selectin, and blood pressure: results from the randomized, controlled Dietary Intervention and VAScular function (DIVAS) study. *Am J Clin Nutr* 2015;102(1):40-8.
16. Weech M, Vafeiadou K, Hasaj M, Todd S, Yaqoob P, Jackson KG, Lovegrove JA. Development of a Food-Exchange Model to Replace Saturated Fat with MUFAs and n-6 PUFAs in Adults at Moderate Cardiovascular Risk. *J Nutr* 2014;144(6):846-55.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28(7):412-9.
18. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. *BMJ* 2008;336(7659):1475-82.
19. Willett WC. Dietary fats and coronary heart disease. *J Intern Med* 2012;272(1):13-24.

20. Guasch-Ferre M, Hu FB, Martinez-Gonzalez MA, Fito M, Bullo M, Estruch R, Ros E, Corella D, Recondo J, Gomez-Gracia E, et al. Olive oil intake and risk of cardiovascular disease and mortality in the PREDIMED Study. *BMC Med* 2014;12:78.
21. de Lorgeril M, Salen P. New insights into the health effects of dietary saturated and omega-6 and omega-3 polyunsaturated fatty acids. *BMC Med* 2012;10:50.
22. Sutherland WH, de Jong SA, Hessian PA, Williams MJ. Ingestion of native and thermally oxidized polyunsaturated fats acutely increases circulating numbers of endothelial microparticles. *Metabolism* 2010;59(3):446-53.
23. Marin C, Ramirez R, Delgado-Lista J, Yubero-Serrano EM, Perez-Martinez P, Carracedo J, Garcia-Rios A, Rodriguez F, Gutierrez-Mariscal FM, Gomez P, et al. Mediterranean diet reduces endothelial damage and improves the regenerative capacity of endothelium. *Am J Clin Nutr* 2011;93(2):267-74.
24. Fernandez JM, Rosado-Alvarez D, Da Silva Grigoletto ME, Rangel-Zuniga OA, Landaeta-Diaz LL, Caballero-Villarraso J, Lopez-Miranda J, Perez-Jimenez F, Fuentes-Jimenez F. Moderate-to-high-intensity training and a hypocaloric Mediterranean diet enhance endothelial progenitor cells and fitness in subjects with the metabolic syndrome. *Clin Sci (Lond)* 2012;123(6):361-73.
25. Hamilton PK, Lockhart CJ, Quinn CE, McVeigh GE. Arterial stiffness: clinical relevance, measurement and treatment. *Clin Sci (Lond)* 2007;113(4):157-70.
26. Pirro M, Schillaci G, Bagaglia F, Menecali C, Paltriccia R, Mannarino MR, Capanni M, Velardi A, Mannarino E. Microparticles derived from endothelial

- progenitor cells in patients at different cardiovascular risk. *Atherosclerosis* 2008;197(2):757-67.
27. Tao J, Wang Y, Yang Z, Tu C, Xu MG, Wang JM. Circulating endothelial progenitor cell deficiency contributes to impaired arterial elasticity in persons of advancing age. *J Hum Hypertens* 2006;20(7):490-5.
 28. Kelly RP, Millasseau SC, Ritter JM, Chowienczyk PJ. Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men. *Hypertension* 2001;37(6):1429-33.
 29. Tan KT, Tayebjee MH, Lynd C, Blann AD, Lip GY. Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. *Ann Med* 2005;37(1):61-6.
 30. van der Zee PM, Biro E, Ko Y, de Winter RJ, Hack CE, Sturk A, Nieuwland R. P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. *Clin Chem* 2006;52(4):657-64.
 31. Feihl F, Liaudet L, Waeber B. The macrocirculation and microcirculation of hypertension. *Curr Hypertens Rep* 2009;11(3):182-9.
 32. Esposito K, Ciotola M, Schisano B, Gualdiero R, Sardelli L, Misso L, Giannetti G, Giugliano D. Endothelial microparticles correlate with endothelial dysfunction in obese women. *J Clin Endocrinol Metab* 2006;91(9):3676-9.
 33. Muller-Ehmsen J, Braun D, Schneider T, Pfister R, Worm N, Wielckens K, Scheid C, Frommolt P, Flesch M. Decreased number of circulating progenitor

- cells in obesity: beneficial effects of weight reduction. *Eur Heart J* 2008;29(12):1560-8.
34. Werner N, Nickenig G. Clinical and therapeutical implications of EPC biology in atherosclerosis. *J Cell Mol Med* 2006;10(2):318-32.
35. Streiner DL. Best (but oft-forgotten) practices: the multiple problems of multiplicity-whether and how to correct for many statistical tests. *Am J Clin Nutr* 2015;102(4):721-8.

Table 1. Baseline characteristics of study subjects¹

	SFA group (n=64)	MUFA group (n=61)	n-6 PUFA group (n=65)
Age, y	45 ± 1	43 ± 1	45 ± 1
Sex, M/F	28 / 36	25 / 36	29 / 36
BMI, kg/m ²	26.5 ± 0.5	26.3 ± 0.5	27.0 ± 0.5
Waist:hip ratio	0.87 ± 0.01	0.85 ± 0.01	0.88 ± 0.01
24h SBP, mm Hg	120 ± 2	120 ± 1	124 ± 2
24h DBP, mm Hg	75 ± 1	74 ± 1	76 ± 1
<i>Fasting serum biomarkers</i>			
Total cholesterol, mmol/L	5.4 ± 0.1	5.5 ± 0.1	5.6 ± 0.2
LDL cholesterol, mmol/L	3.7 ± 0.1	3.7 ± 0.1	3.8 ± 0.1
Triacylglycerol, mmol/L	1.3 ± 0.1	1.2 ± 0.1	1.3 ± 0.1
Glucose, mmol/L	5.1 ± 0.1	5.0 ± 0.1	5.1 ± 0.1
CVD risk score ¹	3.3 ± 0.2	3.0 ± 0.2	3.4 ± 0.2

Data are mean ± SEM. ¹ No significant differences between the groups were identified for any of the baseline characteristics (one-way ANOVA except Chi-square for sex; $P > 0.05$). ¹ Determined using the DIVAS study screening tool (16). CVD: cardiovascular disease; DBP: diastolic blood pressure; SBP: systolic blood pressure.

Figure 1. Effect of replacement of dietary SFA with MUFA or n-6 PUFA on numbers of EPC (A), EMP (B) and PMP (C) expressed as change from baseline.

Data are presented as LSMeans \pm SE for $n=59-65$ subjects per group. There was a significant effect of diet after 16 weeks for EPC, EMP and PMP (overall diet effects: $P \leq 0.05$; general linear model), in which post-hoc analyses (using Tukey correction to adjust for multiple **treatments**) identified significant differences between the SFA diet and both MUFA and n-6 PUFA diets ($*P < 0.05$; $**P < 0.01$; $***P \leq 0.001$). Abbreviations: Δ : change from baseline, EPC: endothelial progenitor cells, EMP: endothelial microparticles, PMP: platelet microparticles.